Clinical trials: EGFR Mutant
Lung Cancer Stage IV
Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs
About 20%-40% of NSCLC patients develop intracranial metastases, and most clinical studies suggest that the survival of lung cancer patients will be significantly shortened once they develop intracranial metastases.
- Trial name
- NCT04519983
- Testing
- Aumolertinib Oral Tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Cancer Hospital, China